528
Background:
Fluoropyrimidines are widely used in the treatment of solid malignancies. Variants in the dihydropyrimidine dehydrogenase (
DPYD
) gene increase the risk of severe fluoropyrimidine-associated toxicity. Following guidance from Ontario Health (Cancer Care Ontario) recommending
DPYD
genotyping...
Sara Ladak, L. Thanabalachandran, Alisia Chen et al.· JCO Oncology Practice· 0 citations
181
Background:
Next-generation sequencing (NGS) is integral to colorectal cancer care, as expanding targeted therapies depend on timely molecular profiling. However, timely processing and access to results depend on a multistep pathway, including biopsy, pathologist review, test initiation, laboratory processi...
L. Thanabalachandran, D. Ali, Avery Newman-Simmons et al.· JCO Oncology Practice· 0 citations
PURPOSE
The role of external beam radiotherapy (EBRT) in differentiated thyroid cancer (DTC) remains debated and is largely guided by retrospective data, much of which predates modern radiotherapy techniques. In this retrospective cohort study, we evaluate outcomes of patients with advanced DTC treated in the modern ra...
Dana Bartolucci, Malvika Agarwal, Xiang Y. Ye et al.· Practical Radiation Oncology· 0 citations
Simple Summary For people with advanced colorectal cancer, choosing the most effective treatment depends on timely genetic testing of the tumour. When these results are delayed or hard to access, treatment may be postponed or started before the best targeted option is known. Because this testing involves many steps, fr...
Luxiga Thanabalachandran, D. Ali, Avery Newman-Simmons et al.· Current Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
